StreetInsider.com News Articles

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

TOKYO, Feb 3, 2026 - (JCN Newswire) - - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced publication of the EAGLE Trial1 - a multicenter randomized controlled study evaluating the CADDIE(TM) device, the first cloud-based Computer-Aided Detection (CADe) application for real-time polyp detection during colonoscopy that is both FDA-cleared and CE-marked. The CADDIE software is the first solution introduced as part of the OLYSENSE(TM) Intelligent Endoscopy Ecosystem.

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

Mon, 02 Feb 2026 19:00:00 -0500

The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

TOKYO and WESTBOROUGH, Mass., Dec 15, 2025 - (JCN Newswire) - - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II. Building on the success of the initial fund, Olympus will deploy $150 million to invest in promising MedTech startup companies focused on Gastrointestinal (GI), Urology and Respiratory.

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

Sun, 14 Dec 2025 17:30:00 -0500

OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A

Olympus Unveils Corporate Strategy